<DOC>
	<DOCNO>NCT00121017</DOCNO>
	<brief_summary>The purpose study determine whether simplify lopinavir/ritonavir-based therapy continue keep viral load low level initial treatment combination Kaletra ( lopinavir/ritonavir ) plus tenofovir emtricitabine .</brief_summary>
	<brief_title>A Study Exploring Induction-Maintenance Kaletra-Based Therapy Versus Sustiva-Based Regimen Previously Non-Treated , HIV-1/HCV Co-Infected Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Subject least 18 year age . Subject 's plasma HIV1 RNA &gt; 1000 copies/mL screen investigator 's opinion , subject require antiretroviral therapy . Subject naive antiretroviral therapy receive &lt; 7 day total antiretroviral therapy &gt; 30 day prior study drug administration . Subject chronic HCV base detectable plasma HCV RNA level ( &gt; 600 IU/mL ) screening . Subject currently undergo treatment HCV infection plan initiate HCV treatment duration study . If female , result urine pregnancy test perform screen Day1/Baseline negative . If female , subject either childbearing potential , defined postmenopausal least one year surgically sterile ( bilateral tubal ligation , bilateral oophorectomy hysterectomy ) , childbearing potential practice one follow method birth control : condom , sponge , foam , jelly , diaphragm intrauterine device , vasectomize partner total abstinence sexual intercourse . Subject breastfeeding . Subject 's vital sign , physical examination laboratory result exhibit evidence acute illness . Subject agrees take drug study , include overthecounter medicine , vitamin , mineral supplement , herbal preparation , alcohol recreational drug without knowledge permission investigator . Subject treat active AIDSdefining opportunistic infection within 30 day initiate study drug . Subject voluntarily sign date informed consent , approve Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) , nature study explain subject opportunity ask question . The informed consent must sign studyspecific procedure perform . Subject history allergic reaction significant sensitivity lopinavir , ritonavir , tenofovir , emtricitabine , lamivudine , efavirenz inert material contain study drug formulation . Subject significant history cardiac , renal , neurologic , psychiatric , oncologic metabolic disease would , opinion investigator , adversely affect his/her participation study . Subject chronic hepatic disease etiology HCV infection ( include hemochromatosis , autoimmune hepatitis , Wilson 's Disease , hepatocellular carcinoma ) . Subject liver biopsy result consistent advance chronic cirrhosis Child Pugh Score `` C '' . Subject currently take require drug contraindicate significant pharmacokinetic interaction study drug course study . For complete information refer current product label locally approve prescribe information lopinavir/ritonavir ( Kaletra ) , efavirenz ( Sustiva ) , tenofovir disoproxil fumarate ( Viread ) , emtricitabine ( Emtriva ) , coformulated emtricitabine/tenofovir disoproxil fumarate ( Truvada ) lamivudine ( Epivir ) . Subject ongoing history drug and/or alcohol abuse psychiatric illness investigator 's opinion could preclude compliance protocol . Subject receive investigational drug vaccine within 30 day prior study drug administration . The screen HIV1 genotype resistance report suggest resistance possible resistance study RTI ( ) lopinavir/ritonavir ; Evidence possible resistance efavirenz ; Presence one follow mutation : RT L1001 , K103N , V106A M , V108I , Y181C I , Y188L , G190A S , P225H , M230L ; Evidence possible resistance emtricitabine lamivudine ; Presence one follow mutation : RTm184V I ; Evidence possible resistance tenofovir ; Presence RT K65R insertion codon 69 , Presence 2 follow mutation : RTm41L , D67N , K70R , L210W ; change T215 , K219Q evidence possible resistance lopinavir/ritonavir ; Presence one follow mutation : protease I47V A , G48V , I50V , V82A F T S , I84V , 190M Presence 3 follow mutation : protease L10F I R V , K20M R , L24I , V32I , L33F , M36I , M46I L , F53L ; change I54 , A71V T , G73S . Screening laboratory analysis show follow abnormal laboratory result : Presence hepatitis B surface antigen ( HBsAg ) antiHBcAB ( Total Ig , Total Bilirubin &gt; /= 2.5x upper limit normal ( ULN ) , Hemoglobin &lt; 8.0 g/dL , Absolute neutrophil count &lt; 750 cells/uL , Platelet count &lt; 50,000/mL , ALT ( SGPT ) AST ( SGOT ) &gt; 5.0x ULN , Creatinine &gt; 1.5x ULN , Calculated creatinine clearance &lt; 50 mL/min , PT &gt; 3.0 second prolonged ULN . For reason , subject consider investigator unsuitable candidate participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>HCV Infection</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>